Answers are grounded in this paper and cite their sources.
The poor prognosis of small cell lung cancer (SCLC) is closely linked to immunosuppressive M2-polarized tumor-associated macrophages (TAMs). While the aryl hydrocarbon receptor (AhR) promotes immunosuppressive myeloid differentiation, its single-cell mechanisms and targeted therapeutics in SCLC remain undefined. Integrating single-cell transcriptomics, network pharmacology, and cell communication analysis, we constructed a comprehensive SCLC atlas identifying AhR as a central immunosuppressive hub. Uniquely, AhR + TAMs displayed a mixed inflammatory-regulatory phenotype rather than a classic M2 signature, acting as pivotal modulators of TME signaling. Screening 137 bioactive compounds from 20 traditional Chinese medicines identified galangin and kaempferol as potential AhR antagonists. Docking and MD simulations predicted compatible occupancy of the AhR ligand-binding domain, which was supported experimentally by SPR binding and by blockade of FICZ- or SCLC-conditioned medium-induced nuclear translocation and transcriptional activity. Consequently, they reversed M2 polarization by downregulating M2 markers and cytokines in an AhR-dependent manner. This work elucidates at single-cell resolution the distinct immunosuppressive role of AhR + TAMs in SCLC and validates galangin and kaempferol as candidate modulators of TAM polarization. Our findings provide an exploratory, hypothesis-generating mechanistic basis for AhR-targeted immunomodulatory strategies aimed at mitigating immunosuppression in SCLC.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: